The pathogenesis of cancer-associated thrombosis

Tatsumi, Kohei

doi:10.1007/s12185-024-03735-x

Cited by 7 publications

(1 citation statement)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One more mechanism for tumor recruitment of myeloid cells is through platelets or coagulation. Cancer is often thrombogenic [378,379], and platelets and coagulation factors promote cancer sustenance, invasion, and metastasis in multiple ways [380][381][382][383]. One mechanism by which platelets promote cancer metastasis is mediating formation of heteroaggregates comprised of cancer cells, fibrinogen, platelets, and leukocytes; cancer cells require this type of complex interactions with neutrophils, monocytes and platelets in order to bind endothelial cells, activate the microvascular endothelium and promote hematogenous metastasis [194,[384][385][386][387].…”

Section: Platelet and Coagulationmentioning

confidence: 99%

Immune Cell Migration to Cancer

Ryan,

Kim,

Lim

2024

Cells

View full text Add to dashboard Cite

Immune cell migration is required for the development of an effective and robust immune response. This elegant process is regulated by both cellular and environmental factors, with variables such as immune cell state, anatomical location, and disease state that govern differences in migration patterns. In all cases, a major factor is the expression of cell surface receptors and their cognate ligands. Rapid adaptation to environmental conditions partly depends on intrinsic cellular immune factors that affect a cell’s ability to adjust to new environment. In this review, we discuss both myeloid and lymphoid cells and outline key determinants that govern immune cell migration, including molecules required for immune cell adhesion, modes of migration, chemotaxis, and specific chemokine signaling. Furthermore, we summarize tumor-specific elements that contribute to immune cell trafficking to cancer, while also exploring microenvironment factors that can alter these cellular dynamics within the tumor in both a pro and antitumor fashion. Specifically, we highlight the importance of the secretome in these later aspects. This review considers a myriad of factors that impact immune cell trajectory in cancer. We aim to highlight the immunotherapeutic targets that can be harnessed to achieve controlled immune trafficking to and within tumors.

show abstract

Section: Platelet and Coagulationmentioning

confidence: 99%

Immune Cell Migration to Cancer

Ryan,

Kim,

Lim

2024

Cells

View full text Add to dashboard Cite

show abstract

Navigating the Landscape of Cancer-Induced Thrombocytopenia: Current Challenges and Emerging Advances

Sharma,

Raut,

Dhikale

et al. 2024

Industrial Microbiology and Biotechnology

View full text Add to dashboard Cite

Venous thrombosis and obesity: from clinical needs to therapeutic challenges

La Rosa,

Montecucco,

Liberale

et al. 2024

Intern Emerg Med

View full text Add to dashboard Cite

Weight bias and stigma have limited the awareness of the systemic consequences related to obesity. As the narrative evolves, obesity is emerging as a driver and enhancer of many pathological conditions. Among these, the risk of venous thromboembolism (VTE) is a critical concern linked to obesity, ranking as the third most common cardiovascular condition. Obesity is recognized as a multifactorial risk factor for VTE, influenced by genetic, demographic, behavioral, and socio-economic conditions. Despite established links, the exact incidence of obesity related VTE in the general population remains largely unknown. The complexity of distinguishing between provoked and unprovoked VTE, coupled with gaps in obesity definition and assessment still complicates a tailored risk assessment of VTE risk. Obesity reactivity, hypercoagulability, and endothelial dysfunction are driven by the so-called ‘adiposopathy’. This state of chronic inflammation and metabolic disturbance amplifies thrombin generation and alters endothelial function, promoting a pro-thrombotic environment. Additionally, the inflammation-induced clot formation—also referred to as ‘immunothrombosis’ further exacerbates VTE risk in people living with obesity. Furthermore, current evidence highlights significant gaps in the management of obesity related VTE, particularly concerning prophylaxis and treatment efficacy of anticoagulants in people living with obesity. This review underscores the need for tailored therapeutic approaches and well-designed clinical trials to address the unique challenges posed by obesity in VTE prevention and management. Advanced research and innovative strategies are imperative to improve outcomes and reduce the burden of VTE in people living with obesity.

show abstract

The pathogenesis of cancer-associated thrombosis

Cited by 7 publications

References 109 publications

Immune Cell Migration to Cancer

Immune Cell Migration to Cancer

Navigating the Landscape of Cancer-Induced Thrombocytopenia: Current Challenges and Emerging Advances

Venous thrombosis and obesity: from clinical needs to therapeutic challenges

Contact Info

Product

Resources

About